Diligence memo · auto-generated · as of July 2, 2026
Symbiomix Therapeutics, LLC
Symbiomix Therapeutics, LLC looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Symbiomix Therapeutics, LLC operates in Pharmaceuticals, based in NEWARK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Symbiomix Therapeutics, LLC has raised $26M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2013-05-03.
Most recent recorded round closed around 2016-04-22.
Valuation (modeled)modeled
Provath models Symbiomix Therapeutics, LLC at approximately $204M (range $13M–$785M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.30× the median modeled value of Series B Pharmaceuticals companies in 2016–2018 (40 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 18 months.
Last raise 10.2 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 3.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 70% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 69% of those peers.
Closest niche peers: LP Investors, LLC, GigaGen, Inc., Vitality Biopharma, Inc., Madrigal Pharmaceuticals, Inc., Slayback Pharma Ltd Liability Co.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.